In Reply We thank Zhang and Huang for their interest in our article1 and the opportunity to further clarify the points that were made. First, we confirm that the reported study period (March 18, 2011, through June 25, 2013) includes the recruitment period, the 14- to 15-week double-blind phase, and the complete 1-year open-label extension. Recruitment was not selective and it actually took slightly less than a year to enroll all 485 patients, which is within the current expectations for this patient population. Second, 367 patients completed the double-blind phase of the study and agreed to enter the open-label extension. Of these, 286 patients (78%) completed the entire 1-year follow-up period. We do not agree that a 12% rate of dropout during a double-blind study and 22% dropout rate during 1 year of follow-up should be considered unusual or large, and our data are similar to those reported in similar studies conducted among a similar patient population.2,3 Finally, we confirm that all secondary outcomes are accurately described and presented within Table 2 of the article.1
Lees AJ, Rocha J, Soares-da-Silva P. Concerns Regarding Opicapone as Adjunct to Levodopa Therapy–Reply. JAMA Neurol. 2017;74(7):873. doi:https://doi.org/10.1001/jamaneurol.2017.0726
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: